UK Biotech Monument Uses Repurposed Drugs To Target CNS Conditions

Initial Programs In Cognitive Impairment In Schizophrenia, Post-Operative Cognitive Decline

 
• By Sten Stovall
  
Emerging Company Profile: Monument Therapeutics
Spinout has access to vast library of validated CNS biomarkers created by its parent • Source: Alamy
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Neurological

More from Therapeutic Category